• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
165737 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

$ |; G% W; @3 Z2 M2 Q& N2 K1 x6 N可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  5 m8 G' e! m# p# Z2 v1 x' K1 m

5 b1 o. Z" E: C  D) s, _% |6 L# z# Y6 U7 n' d* ]9 I1 X# ?- g
Sub-category:/ n! B7 G4 H8 y; S" t+ A
Molecular Targets 9 Y1 p  f4 i  Q' ?" U8 N8 g

; G5 _5 m6 O' F$ R( I0 L+ e4 J# ~! s
Category:; Q* r* {4 a# P2 y/ S
Tumor Biology - L! o" Z% d+ D8 h

7 L6 x  Y1 e# F+ I' p4 ~) q9 n
4 a! Y; }. N" e" B" KMeeting:
# y0 t) `* g  f2 M8 y3 t' e8 |2011 ASCO Annual Meeting 8 e. a* }: z1 y& O/ T, ~4 ?

! w6 u* q8 _. I6 d4 t6 ]( m2 k2 @8 [. o1 T* G! ^
Session Type and Session Title:; y+ @2 {2 J4 {9 t2 K9 }
Poster Discussion Session, Tumor Biology " F) Z1 [. C9 e; H4 ?

' A1 P; e! Y# }3 Y
& N: G9 s' X1 W" u" C; JAbstract No:
3 V) A& A/ a; [! n7 a# c8 i10517
) {0 C! F% v( U6 h5 }- ^* @7 [6 B/ d- V7 w/ u( C

) z% @: p( P. T7 ]: j! o$ QCitation:8 g8 o/ K4 ^$ ^0 x! }
J Clin Oncol 29: 2011 (suppl; abstr 10517)
$ o0 Z. h- C0 I' N
1 J9 h5 {7 A% W; C' Y6 U& M
) {) v+ m1 H2 z' ^  k& eAuthor(s):
& X/ l( _' S3 P8 sJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
5 }2 ~$ R# {. p1 E( f9 b: [, G" |' ~0 r% B% S# ?

  ?1 |% C) s7 z' D# C' o
$ f$ S; g" y* g6 FAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
7 T- j: ]  Y8 K. H6 u" m% H) C* C0 d1 n/ x7 ~7 ]# c, _# b8 ]
Abstract Disclosures5 K7 d; N3 V; n8 E* R
" N# M, d/ g) }+ |( Y- _; ~
Abstract:5 W) m9 P0 }7 g

' ]$ u1 g8 `5 ], X  o: E3 n
5 E) B, ~- Q: C0 k+ E6 B0 B! F6 _! nBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.% O3 `  k' ]7 ^

+ {. `' E1 H! {* m0 ]* n 2 O+ Q) N' E  ~4 g2 t5 Y% k
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 . b. N: H5 E5 y9 J  b' p/ r5 h: |" C
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

8 B# i. ~2 T' h  C4 m化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 - u. p1 s: Q2 Z  Z
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。/ v, ^% c7 m* B; v# M, D( f& i4 i' N! d
ALK一个指标医院要900多 ...

3 S5 v6 c1 E, N! j3 b( c8 V平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?; ~; y. ?4 W4 ?9 R1 E
0 |3 F- z; \8 y  T
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表